Finemedix Co., Ltd.

As of June 30, 2026, Finemedix Co., Ltd. carries a market capitalization of 28.18B, placing it among publicly traded companies globally. Its enterprise value stands at 24.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Finemedix Co., Ltd. has 5.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.47, and the price-to-book ratio stands at 1.47.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 24.73B versus a market cap of 28.18B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Finemedix Co., Ltd. maintains a current ratio of 10.83, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.66, indicating elevated leverage, while an interest coverage ratio of -10.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Finemedix Co., Ltd. posted a negative return on equity (ROE) of -3.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.48, reflecting losses generated across the asset base. The company generates approximately 149.86M in revenue per employee across its workforce of 76.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.16 indicates how many times Finemedix Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Finemedix Co., Ltd. recorded an income tax benefit of -542.64M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.14B and -599.38M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Finemedix Co., Ltd.'s stock has declined approximately 29.10% over the past 52 weeks. The 50-day moving average sits at 6,144.50, while the 200-day moving average is 6,365.45.

Over the twelve months ended June 30, 2026, Finemedix Co., Ltd. generated 11.43B in revenue and converted that into -599.38M in net income, yielding earnings per share of -110.37. EBITDA reached -234.18M, while operating income came in at -1.17B.

As of June 30, 2026, Finemedix Co., Ltd. holds 5.68B in cash and equivalents against 2.23B in total debt, resulting in a net debt position of -2.14B. Total book value stands at 19.13B, with working capital of 12.20B providing operational flexibility.

Finemedix Co., Ltd. produced 919.75M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -226.04M in capital expenditures, free cash flow totaled 693.71M - equivalent to 127.74 per share.

Over the twelve months ended June 30, 2026, Finemedix Co., Ltd. posted a gross margin of 51.93, reflecting its pricing power and cost economics. The operating margin of -10.21 and net profit margin of -5.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.46, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Finemedix Co., Ltd. shareholders.

As of June 30, 2026, Finemedix Co., Ltd. has an Altman Z-Score of 4.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.